RECORD // Company

Biocryst Pharmaceuticals Inc

Built 2026-11-22T02:39:54Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (2 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

Gleif lei (1)
SEC EDGAR (1)
Matched by name only, not merged (5)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • BioCryst Pharmaceuticals · Ctgov · exact name match to 'BIOCRYST PHARMACEUTICALS INC' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • BIOCRYST PHARMACEUTICALS INC · Epa echo · same registered legal name as 'BIOCRYST PHARMACEUTICALS INC' Possible match based on name, not a shared identifier. Compare the records. Compare
  • BIOCRYST PHARMACEUTICALS, INC. · Epa echo · same registered legal name as 'BIOCRYST PHARMACEUTICALS INC' Possible match based on name, not a shared identifier. Compare the records. Compare
  • BIOCRYST PHARMACEUTICALS, INC. · Ny corps · same registered legal name as 'BIOCRYST PHARMACEUTICALS INC' Possible match based on name, not a shared identifier. Compare the records. Compare
  • BIOCRYST PHARMACEUTICALS INC · USAspending · same registered legal name as 'BIOCRYST PHARMACEUTICALS INC' Possible match based on name, not a shared identifier. Compare the records. Compare

6 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-04 · accession 0001628280-26-070112

ItemValuePeriodFormFiledAccessionReport
Revenue$180,292,0003 months ended 2026-09-3010-Q2026-11-040001628280-26-0701122026-11-22 02:39 UTCReport an error
Net income (loss)$37,916,0003 months ended 2026-09-3010-Q2026-11-040001628280-26-0701122026-11-22 02:39 UTCReport an error
Interest expense$21,185,0003 months ended 2026-09-3010-Q2026-11-040001628280-26-0701122026-11-22 02:39 UTCReport an error
Cash and cash equivalents$96,971,000at 2026-09-3010-Q2026-11-040001628280-26-0701122026-11-22 02:39 UTCReport an error
Contract liabilities, current$10,535,000at 2026-09-3010-Q2026-11-040001628280-26-0701122026-11-22 02:39 UTCReport an error
Contract liabilities, noncurrent$11,614,000at 2026-09-3010-Q2026-11-040001628280-26-0701122026-11-22 02:39 UTCReport an error

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0000882796
Ticker
BCRX
EIN
621413174
UEI
MGXADJ6SCLJ5
CUSIP
09058V103
Record ID
sx:sec:0000882796

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

33 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-16SEC EDGAR company profile2026-11-22 02:39 UTCReport an error
SIC industry2836 Biological Products, (No Diagnostic Substances)2026-11-16SEC EDGAR company profile2026-11-22 02:39 UTCReport an error
State of incorporationDE2026-11-16SEC EDGAR company profile2026-11-22 02:39 UTCReport an error
Fiscal year end (MMDD)12312026-11-16SEC EDGAR company profile2026-11-22 02:39 UTCReport an error
Business address4505 EMPEROR BOULEVARD, SUITE 200, DURHAM, NC, 277032026-11-16SEC EDGAR company profile2026-11-22 02:39 UTCReport an error
ExchangesNasdaq2026-11-16SEC EDGAR company profile2026-11-22 02:39 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$874,837,0002025-12-3110-K, XBRL RevenueFromContractWithCustomerIncludingAssessedTax2026-11-22 02:39 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$263,861,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-22 02:39 UTCReport an error
Total assets (at 2025-12-31)$514,158,0002025-12-3110-K, XBRL Assets2026-11-22 02:39 UTCReport an error
Stockholders' equity (at 2025-12-31)$-119,153,0002025-12-3110-K, XBRL StockholdersEquity2026-11-22 02:39 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$89,736,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 02:39 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$347,369,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 02:39 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$2,468,0002025-12-3110-K, XBRL PaymentsToAcquireProductiveAssets2026-11-22 02:39 UTCReport an error
Long-term debt (at 2025-12-31)$02025-12-3110-K, XBRL LongTermDebtNoncurrent2026-11-22 02:39 UTCReport an error
Operating lease liabilities (at 2025-12-31)$8,888,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-22 02:39 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-04)On November 4, 2026, BioCryst Pharmaceuticals, Inc. (the “Company”) issued a press release announcing recent corporate developments and its financial results for the third quarter ended September 30, 2026, which also referenced a conference call and webcast to discuss these recent corporate developments and financial results. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.2026-11-04SEC EDGAR 8-K 0001171843-26-007097 (text as filed, excerpt)2026-11-22 02:39 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-11-04)The information furnished on Exhibit 99.1 is incorporated by reference under this Item 7.01 as if fully set forth herein. The information in this Current Report on Form 8-K, including Exhibit 99.1 furnished hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.2026-11-04SEC EDGAR 8-K 0001171843-26-007097 (text as filed, excerpt)2026-11-22 02:39 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-08-05)On August 5, 2026, BioCryst Pharmaceuticals, Inc. (the “Company”) issued a press release announcing recent corporate developments and its financial results for the second quarter ended June 30, 2026, which also referenced a conference call and webcast to discuss these recent corporate developments and financial results. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.2026-08-05SEC EDGAR 8-K 0001171843-26-005223 (text as filed, excerpt)2026-11-22 02:39 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-08-05)The information furnished on Exhibit 99.1 is incorporated by reference under this Item 7.01 as if fully set forth herein. The information in this Current Report on Form 8-K, including Exhibit 99.1 furnished hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.2026-08-05SEC EDGAR 8-K 0001171843-26-005223 (text as filed, excerpt)2026-11-22 02:39 UTCReport an error
8-K Item 2.05, Costs Associated with Exit or Disposal Activities (filed 2026-08-04)On June 29, 2026, the Company announced its plan to discontinue the Company’s internal discovery programs and close its Discovery Center of Excellence facility in Birmingham, Alabama (the “Plan”) as part of the Company’s ongoing strategic evolution to strengthen its rare disease pipeline. At the time of the Original Report, the Company was not able to make a good faith estimate of the costs it would incur in connection with the Plan. The Company now estimates that it will incur between $6.2 and $7.5 million in one-time expenses in connection with employee termination benefits and severance, of which approximately $5.3 to $6.6 million are expected to be cash expenditures. While the Company…2026-08-04SEC EDGAR 8-K 0001171843-26-005168 (text as filed, excerpt)2026-11-22 02:39 UTCReport an error
Plan (pension, plan no. 001)BIOCRYST PHARMACEUTICALS, INC. 401(K) RETIREMENT PLAN: 551 participants, assets $94,150,8222025-12-31DOL EBSA Form 5500 public datasets (dataset)2026-11-22 02:39 UTCReport an error
Largest institutional holder #1 (13F as filed): BlackRock, Inc.$238,930,3602026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 02:39 UTCReport an error
Largest institutional holder #2 (13F as filed): RA CAPITAL MANAGEMENT, L.P.$158,271,8602026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 02:39 UTCReport an error
Largest institutional holder #3 (13F as filed): STATE STREET CORP$151,910,9802026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 02:39 UTCReport an error
Largest institutional holder #4 (13F as filed): DEERFIELD MANAGEMENT COMPANY, L.P.$150,964,0302026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 02:39 UTCReport an error
Largest institutional holder #5 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$113,642,3602026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 02:39 UTCReport an error
Largest institutional holder #6 (13F as filed): VANGUARD PORTFOLIO MANAGEMENT LLC$111,391,5802026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 02:39 UTCReport an error
Largest institutional holder #7 (13F as filed): TCG Crossover Management, LLC$110,209,6802026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 02:39 UTCReport an error
Largest institutional holder #8 (13F as filed): PERCEPTIVE ADVISORS LLC$103,088,8802026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 02:39 UTCReport an error
Largest institutional holder #9 (13F as filed): Jupiter Topco LLC$95,268,3662026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 02:39 UTCReport an error
Largest institutional holder #10 (13F as filed): Vestal Point Capital, LP$83,000,0002026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 02:39 UTCReport an error
Federal award transactions, fiscal year 2026 (this one registration only)$6,624.422026-09-30USAspending recipient profile2026-11-22 02:39 UTCReport an error
Number of federal award transactions, fiscal year 2026 (this one registration only)132026-09-30USAspending recipient profile2026-11-22 02:39 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.